Associated Papers
Rare Germline Variants in CDKN2A-Negative Children and Adolescents With Cutaneous Melanoma.
Johansson PA et al.
Pigment Cell & Melanoma Research, 2026
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.
Montellier E et al.
Ebiomedicine, 2026
41370968 (PubMed )
Supplement: mmc2.xlsx › Table_S1
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
41167083 (PubMed )
Supplement: mmc5.xlsx › Table_S12B
A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.
Fortuno C et al.
Genome Medicine, 2025
41126324 (PubMed )
Supplement: 13073_2025_1536_MOESM2_ESM.xlsx › Table_S2
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
41022739 (PubMed )
Supplement: 41467_2025_63528_MOESM7_ESM.xlsx › Sheet1
Clinicopathologic and Molecular Characterization of Basal Cell Carcinoma Arising at Sun-protected Sites.
Draper E et al.
The American Journal of Surgical Pathology, 2025
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.
Montellier E et al.
Iscience, 2024
39634561 (PubMed )
Supplement: mmc2.xlsx › TableS1
Comprehensive classification of TP53 somatic missense variants based on their impact on p53 structural stability.
Tam B et al.
Briefings in Bioinformatics, 2024
39140857 (PubMed )
Supplement: table_s1_bbae400.xlsx › Sheet1
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K et al.
Scientific Reports, 2023
36964217 (PubMed )
Supplement: 41598_2023_32092_MOESM1_ESM.xlsx › Suppl._table_S1
Profile of esophageal squamous cell carcinoma mutations in Brazilian patients.
Munari FF et al.
Scientific Reports, 2021
The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy.
Jacob SL et al.
Heliyon, 2020
32420470 (PubMed )
Supplement: mmc1.pdf
K120R mutation inactivates p53 by creating an aberrant splice site leading to nonsense-mediated mRNA decay.
Lee SY et al.
Oncogene, 2019
Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO et al.
Nature Genetics, 2018
30224644 (PubMed )
Supplement: NIHMS1501645-supplement-3.xlsx › Sheet1
A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
Monteith JA et al.
Molecular Oncology, 2016
Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery.
Hudson AM et al.
Cancer Research, 2014
TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B et al.
Human Mutation, 2014
24665023 (PubMed )
Supplement: supplement_1.pdf
Discrimination of DNA binding sites by mutant p53 proteins.
Thukral SK et al.
Molecular and Cellular Biology, 1995
Select a paper to view details